Read news on anti-PD-1 antibodies with our app.
Read more in the app
Neoadjuvant dual immuno-combination therapy with anti-LAG3 and anti-PD-1 antibodies is feasible and safe for resectable non-small cell lung cancer - EurekAlert!
